BCTX · BriaCell Therapeutics Corp.
Substantial doubt about the company's ability to continue as a going concern.
“The uncertainty of the Company’s ability to raise such financial capital casts substantial doubt on the Company’s ability to continue as a going concern.”View the 10-Q filed Jun 9, 2026
Share-repurchase activity from the company's own XBRL filings — cash spent on equity repurchases (common and preferred combined, as reported) per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2023-07-31 | $47,294 | 10-K, filed 2024-10-29 |
| 2022-07-31 | $10,171,732 | 10-K, filed 2023-10-25 |